TLDR DCPA is a chronic skin condition affecting the legs, often misdiagnosed, and needs more research for better understanding and treatment.
The article "Dermatitis Cruris Pustulosa et Atrophicans: Scarring Alopecia Beyond Scalp Hair" explores a rare dermatological condition that causes scarring alopecia on the lower limbs and other body areas, not just the scalp. It highlights the clinical features, diagnosis, and treatment options, stressing the importance of early intervention to prevent permanent hair loss and scarring. The condition, first described in Nigeria in 1952, involves multifactorial etiology and is often overlooked. Current treatments, including antiseptics, topical mupirocin, and systemic antibiotics, show variable success. A case study of a 34-year-old Bangladeshi man demonstrated significant improvement with isotretinoin after other treatments failed. The article underscores the need for further research to better understand and manage this chronic and therapy-refractory condition.
14 citations,
September 2009 in “International Journal of Dermatology” DCPA is a chronic leg infection often related to Staphylococcus aureus, affecting mostly young men in India.
11 citations,
January 2009 in “Indian journal of dermatology, venereology, and leprology” DCPA is a chronic skin condition affecting the lower limbs, mainly in men, with unclear causes and treatments that often don't work well.
112 citations,
July 2008 in “Dermatologic Therapy” Folliculitis decalvans is a rare scalp condition causing scarring hair loss, treated with long-term antibiotics and other medications, but it often comes back and is hard to manage.
66 citations,
June 2018 in “British Journal of Dermatology” European guidelines recommend regular eye and ear exams, skin care, vitamin D supplements, and cautious use of medications for managing congenital ichthyoses.
23 citations,
April 2018 in “Journal der Deutschen Dermatologischen Gesellschaft” Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
17 citations,
August 2015 in “Expert Opinion on Pharmacotherapy” The document concludes that oral finasteride and topical minoxidil are effective for genetic hair loss, while other treatments for different types of hair loss show promise but need more research.
